| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | EVP, Research & Product Dev. | Chief Scientific Officer
2 companies
Sander van Deventer last filed a Form 4 in October 2020, as EVP, Research & Product Dev. at QURE. The filings on record cover 2 companies. Sander van Deventer's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 61,599 shares of QURE. The QURE filings lean toward selling, a net 9,570 shares.
Sander van Deventer has 14 Form 4 filings on record from January 2017 to October 2020, across 2 companies: Director at HOOKIPA Pharma (HOOK), 2019–2020; EVP, Research & Product Dev. at uniQure (QURE), 2017–2020.
The 20 reported transactions were 9 option or other derivative awards, 7 stock awards and 4 open-market sales.
Counted by filing, the open-market trades come to no purchases and 3 sales worth about $291K.
The largest open-market sale was 2,227 shares of QURE at an average $61.61 on January 28, 2020, about $137K.
Shares as reported in the last Form 4 for each company; the most recent is from October 2020. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.